Literature DB >> 8439824

Prevention of ventricular remodelling post myocardial infarction: timing and duration of therapy.

B I Jugdutt1.   

Abstract

OBJECTIVE: To review the evidence for the temporal pathophysiological evolution of structural, topographic and functional changes during remodelling post infarction, and how the timing and duration of therapeutic interventions for limiting remodelling might influence outcome. DATA SOURCES: Published English language literature. STUDY SELECTION: The focus was on experimental and clinical studies relating to modification of post infarct remodelling as well as pertinent clinical trials with clinical outcome and mortality end-points. DATA EXTRACTION: An objective determination of the timing and duration of therapy from the indexed infarction, and the rationale for the approach and its possible relation to measured outcome parameters. DATA SYNTHESIS: Several strategies targeted to salvage ischemic myocardium and unload the left ventricle have proven effective in limiting remodelling. Because remodelling begins very early and is a staged and progressive pathophysiological process, timing and duration of therapy are likely to have a profound effect on outcome. Different outcomes can be expected depending on whether therapy is begun very early (during the infarction process), early (after completion of the infarction process but before significant deposition of infarct collagen has occurred), late (after infarct collagen has peaked and infarct healing is completed) or very late (after healing is completed). Different outcomes can also be expected with therapy that spans one or more of these stages. Maximum benefit might be expected from therapy that is begun very early, spans the entire healing process and extends beyond. Two-dimensional echocardiograms can be used to assess the impact of therapies on remodelling and function. Very early thrombolysis and low dose intravenous nitroglycerin followed by prolonged angiotensin-converting enzyme inhibition and/or nitrate appear to be a very promising algorithm.
CONCLUSIONS: The optimal therapeutic strategy for limiting post infarct remodelling should recognize the pathophysiological staging of the process and be targeted at preventing infarction, early expansion and progressive dilation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8439824

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  16 in total

1.  Endocannabinoids as mediators in the heart: a potential target for therapy of remodelling after myocardial infarction?

Authors:  C Robin Hiley; William R Ford
Journal:  Br J Pharmacol       Date:  2003-04       Impact factor: 8.739

Review 2.  STEMI and heart failure in the elderly: role of adverse remodeling.

Authors:  Anwar Jelani; Bodh I Jugdutt
Journal:  Heart Fail Rev       Date:  2010-09       Impact factor: 4.214

3.  Therapeutic drugs during healing after myocardial infarction modify infarct collagens and ventricular distensibility at elevated pressures.

Authors:  Bodh I Jugdutt; Halliday Idikio; Richard R E Uwiera
Journal:  Mol Cell Biochem       Date:  2007-05-09       Impact factor: 3.396

Review 4.  Pleiotropic effects of cardiac drugs on healing post-MI. The good, bad, and ugly.

Authors:  Bodh I Jugdutt
Journal:  Heart Fail Rev       Date:  2008-02-07       Impact factor: 4.214

Review 5.  Current and novel cardiac support therapies.

Authors:  Bodh I Jugdutt
Journal:  Curr Heart Fail Rep       Date:  2009-03

Review 6.  In vivo assessment of regional mechanics post-myocardial infarction: A focus on the road ahead.

Authors:  Eva Romito; Tarek Shazly; Francis G Spinale
Journal:  J Appl Physiol (1985)       Date:  2017-02-23

Review 7.  Endocannabinoids and the heart.

Authors:  C Robin Hiley
Journal:  J Cardiovasc Pharmacol       Date:  2009-04       Impact factor: 3.105

8.  Relationship of sustained brain natriuretic peptide release after reperfused acute myocardial infarction with gated SPECT infarct measurements and its connection with collagen turnover and left ventricular remodeling.

Authors:  Giampaolo Cerisano; Renato Valenti; Roberto Sciagrà; Paolo Domenico Pucci; Mariasilvia Tommasi; Silvia Raspanti; Alberto Pupi; Emilio Vincenzo Dovellini; David Antoniucci
Journal:  J Nucl Cardiol       Date:  2008-07-31       Impact factor: 5.952

9.  Apoptosis after reperfused myocardial infarction: Role of angiotensin II.

Authors:  Bodh I Jugdutt
Journal:  Exp Clin Cardiol       Date:  2004

Review 10.  Captopril. A review of its pharmacology and therapeutic efficacy after myocardial infarction and in ischaemic heart disease.

Authors:  G L Plosker; D McTavish
Journal:  Drugs Aging       Date:  1995-09       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.